News
3 Bargain Biotech Stocks You Can Buy Today
You might have heard that the stock market is overpriced after years of solid gains. And it is. That doesn't mean every stock is overpriced, though.Actually, several biotech stocks look....
Why Celldex Therapeutics, Inc. Jumped Higher Today
Celldex Therapeutics (NASDAQ: CLDX) closed on Monday up 12.8%, with no apparent news to justify the double-digit gain by the biotech company.The move follows an 8.1% jump on Friday. Sometimes,....
3 Warren Buffett Stocks for Retirees
Warren Buffett is arguably the most revered investor on the planet. Over the course of more than six decades he's turned less than $10,000 into a net worth of nearly $79 billion. What's truly....
3 Warren Buffett Stocks for Retirees
Warren Buffett is arguably the most revered investor on the planet. Over the course of more than six decades he's turned less than $10,000 into a net worth of nearly $79 billion. What's truly....
This Marijuana Stock Is On an 8-Day Losing Streak -- Is It Time to Buy?
Over the trailing year, there's arguably been no better-performing industry than marijuana and marijuana stocks. A majority of pot stocks have moved significantly higher over the past year, with a....
3 Top Marijuana Stocks to Buy This Fall
Marijuana stocks weren't all that hot in the first half of 2017. The situation began to turn around for several leading marijuana stocks in the summer, though. What's the outlook for fall? Pretty....
AbbVie's Unfazed by the Risk of Generic Humira
Over 60% of AbbVie Inc.’s (NYSE: ABBV) sales come from demand for Humira -- an autoimmune-disease drug prescribed to patients with a variety of conditions -- that racks up sales of $16 billion per....
Better Buy: Kimberly-Clark Corp. vs. Johnson & Johnson
There aren't many companies that can grow sales and profits through a wide range of market conditions. But both Kimberly-Clark (NYSE: KMB), the consumer goods specialist, and Johnson & Johnson....
Better Buy: Kimberly-Clark Corp. vs. Johnson & Johnson
There aren't many companies that can grow sales and profits through a wide range of market conditions. But both Kimberly-Clark (NYSE: KMB), the consumer goods specialist, and Johnson & Johnson....
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ: JUNO) are rallying 11.3% higher at 3 p.m. EDT.Juno Therapeutics shares have been rallying since....
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ: JUNO) are rallying 11.3% higher at 3 p.m. EDT.Juno Therapeutics shares have been rallying since....
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ: JUNO) are rallying 11.3% higher at 3 p.m. EDT.Juno Therapeutics shares have been rallying since....
Why Exelixis, Inc. Slumped Today
Exelixis (NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an analyst at Leerink Partners downgraded the biotech to market perform. Management also sold some shares, which could be contributing....
This Trial Failure Dropped Versartis Inc 86.6% and Lifted Ascendis Pharma 51.4%
Shares of biopharma Versartis (NASDAQ: VSAR) crashed nearly 87% Friday after somavaratan, the company's lead drug candidate, did not meet its primary endpoint in the phase 3 Velocity trial. The....
This Trial Failure Dropped Versartis Inc 86.6% and Lifted Ascendis Pharma 51.4%
Shares of biopharma Versartis (NASDAQ: VSAR) crashed nearly 87% Friday after somavaratan, the company's lead drug candidate, did not meet its primary endpoint in the phase 3 Velocity trial. The....
AstraZeneca Stock Upgraded: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
AstraZeneca Stock Upgraded: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?
Last week, Gilead Sciences (NASDAQ: GILD) announced that it was borrowing $3 billion. That's billion with a "B."The company doesn't really need the money. It was sitting on $36.6 billion in cash,....
Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?
Last week, Gilead Sciences (NASDAQ: GILD) announced that it was borrowing $3 billion. That's billion with a "B."The company doesn't really need the money. It was sitting on $36.6 billion in cash,....
Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?
Last week, Gilead Sciences (NASDAQ: GILD) announced that it was borrowing $3 billion. That's billion with a "B."The company doesn't really need the money. It was sitting on $36.6 billion in cash,....
3 Big Biotech Stocks to Buy This Fall
A change in season presents a good time to look for great stocks to buy. And one of the best places to look is in the biotech industry. Biotech stocks in general are trouncing the S&P 500....
These 3 Stocks Are Priced for Perfection. Can They Deliver?
You expect a top-ranked football team to play well every game. You expect the Kentucky Derby winner to place in the Preakness Stakes. And you expect a stock with a high valuation to generate....
Better Buy: Celgene Corporation vs. Merck & Co., Inc.
Based on recent history, Celgene Corporation (NASDAQ: CELG) and Merck & Co. (NYSE: MRK) stocks don't even belong in the same league. Celgene stock is up more than 270% over the past five....
Better Buy: Celgene Corporation vs. Merck & Co., Inc.
Based on recent history, Celgene Corporation (NASDAQ: CELG) and Merck & Co. (NYSE: MRK) stocks don't even belong in the same league. Celgene stock is up more than 270% over the past five....
3 Biotech Stocks With Major Catalysts Incoming
Axovant Sciences Ltd (NASDAQ: AXON) and PTC Therapeutics, Inc. (NASDAQ: PTCT) have drugs in late-stage development that could propel them to profitability over the next few years. Gilead Sciences,....